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Objectives. To assess bone health in a cohort of nonjaundiced children with biliary atresia (BA) and the eﬀect of growth
and development on bone outcomes. Methods. Children ages one to eighteen years receiving care from Children’s Hospital of
Philadelphia were recruited. Each child was seen once and assessed for growth, pubertal development, concurrent medications,
bilirubin, ALT, albumin, vitamin D status, bone mineral density (BMD), and bone mineral content (BMC) of the lumbar spine
and whole body. Results. BMD declined signiﬁcantly with age, and upon further analysis with a well-phenotyped control cohort,
it was found that BMC was signiﬁcantly decreased for both lumbar spine and whole body, even after adjustment for confounding
variables. An age interaction was identiﬁed, with older subjects having a signiﬁcantly greater impairment in BMC. Conclusions.
These preliminary results demonstrate that children with BA, including those without jaundice, are likely to have compromised
bone health even when accounting for height and puberty, which are common confounding factors in chronic disease. Further
investigation is needed to identify the determinants of poor bone mineral status and to develop strategies to prevent osteoporosis
later in life.
Copyright © 2009 Rachel A. Kramer et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Biliary atresia (BA) is an infantile liver disease resulting in
a progressive ﬁbro-obliteration of the biliary tree [1]. Suc-
cessful surgical hepatoportoenterostomy promotes biliary
drainage, but does not halt the hepatic inﬂammatory process
[2]. Follow-up care includes serological assessment of both
total and direct bilirubin and alanine transferase, which are
surrogate markers of cholestasis and inﬂammation, respec-
tively. The approach to clinical management is to optimize
growthandnutrition,yetrarelyisbonehealthassessedunless
thereispresenceofjaundice,ahistoryoffracture,inadequate
vitamin D repletion, or exposure to medications that may
aﬀect bone health such as corticosteroids.
Bone disease among patients with liver problems is most
frequently discussed in the context of chronic cholestasis
and fat-soluble vitamin deﬁciency [3–8]. However, it is
now known that not only malabsorption of vitamin D and
calcium [3–10], but also a host of cytokines [6, 9, 11–13]
can contribute to bone loss. A number of other inﬂamma-
tory diseases such as inﬂammatory bowel disease [14–18],
rheumatoid arthritis [19], juvenile idiopathic arthritis [20],
and systemic lupus erythematosus [21], have documented
low bone mineral density and, in some studies, resultant
osteopenia and osteoporosis. Since BA is an inﬂammatory
disorder [1, 22], with ongoing issues of malabsorption
present even when surgery is successful, it is postulated that
bone health might be compromised even when jaundice is
not present.
This preliminary study assessed bone health in a group
of nonjaundiced children with BA from ages one to eighteen
years. Since growth and maturation may be compromised in
a chronic disease such as BA, we used normative data and an
analysis that accounted for confounding variables of height
and puberty as well as race and gender.2 Gastroenterology Research and Practice
2.MaterialsandMethods
2.1. Study Subjects. A l ls u b j e c t sw i t hB Ah a du n d e r g o n ea
Kasai procedure and none had received a liver transplant
at the time of enrollment. In addition, none of the BA
subjects had received steroids post-Kasai. Subjects were
excluded if they had any other chronic illness known to
aﬀect growth, pubertal development or bone health such
as renal insuﬃciency, thyroid disease, parathyroid disease,
or growth hormone insuﬃciency. Hologic control data was
used for the cohort of 16. However, due to limitations of
that control data (not controlled for ethnicity or tanner) we
also performed an analysis using a well-studied local cohort
of 178 healthy control subjects, ages 4 to 18 years, recruited
from the pediatric clinics and surrounding community.
Subjects with medical conditions or medications potentially
aﬀecting growth and development were excluded. Informed
consentwasobtainedfromeachsubject’slegalguardianprior
to the study, and assent was obtained from subjects aged six
years and older. The protocol was approved by the CHOP
Institutional Review Board.
2.2. Height, Weight, and Pubertal Assessment. All subjects
were evaluated in the Nutrition and Growth Laboratory. On
the day of the DXA measurement, height and weight mea-
surements were obtained in triplicate using a wall-mounted
stadiometer and digital scale, respectively; the mean of the
three measures was used in the analysis. Pubertal status was
evaluated by physical exam and classiﬁed according to the
method of Tanner [23]. Age and gender speciﬁc standard
deviation scores (z-scores) for height (HAZ), weight (WAZ)
and body mass index (BMIZ) were calculated using the
Center for Disease Control 2000 Growthcharts [24].
2.3. Laboratory and Bone Age Assessment. For the BA group,
fasting samples were obtained for total bilirubin, direct
bilirubin, albumin, alanine transferase (ALT), and 25–OH
vitamin D levels (EXOTERIX INC. Laboratory Services,
competitive protein binding assay). Bone age was obtained
onthesamedayastheDXAscan,andscoredaccordingtothe
Tanner-Whitehouse 2 (TW2) method [25]. A single observer
scored all radiographs of the left hand and wrist. Three diet
records were assessed for calcium intake.
2.4. DXA Measures. Bone mass in the posterio-anterior
lumbar spine (L1–4) and whole body was measured by DXA
(Hologic QDR 2000, Waltham, Mass, USA) with a fan
beam in the array mode. All subjects were measured on
the same machine. The measurements were performed using
standard positioning techniques. Quality control scans were
performeddailyusingasimulatedL1–4 lumbarspinemadeof
hydroxyapatite encased in epoxy resin. In our institution, the
in vitro coeﬃcient of variation was less than 0.6% and the in
vivo coeﬃcient of variation in adults was less than 1%.
The DXA scans were analyzed to generate measures of
vertebral projected bone area (cm2), BMC (g) and areal
bone mineral density (BMD, g/cm2). Because the standard
software for the analysis of the lumbar spine frequently
fails to detect a complete bone map in children, all lumbar
spine scans were analyzed with the low-density software, as
previously described [26].
2.5. Statistics. The BMC of children with BA were evaluated
relative to the healthy control group. Mean diﬀerences in
the demographic and anthropometric outcomes between BA
subjects and controls were assessed using the t-test. Two-
sided tests of hypotheses were used and a P-value <.05 was
considered signiﬁcant. The race and gender distributions
were compared using the Chi-square test.
Due to inadequacies of Hologic normative data for this
generation machine [27], we recruited our own separate
controlcohortandinvestigatedBMC.Theprimaryoutcomes
were BMC of the spine and whole body, less the head.
Assessment of BMC in children and adolescents required
adjustment for age and body size. The relationship between
BMC and age or body size is nonlinear and heteroscedastic.
Therefore, all continuous variables were natural log trans-
formed for multiple regression analysis to assess diﬀerences
between the BA and control groups adjusting for important
covariates. A polynomial term for age was added to the
models since the natural log transformation did not account
for the non-linear increase in BMC with age. Dummy vari-
ables for black ethnicity and female gender were included in
the models because of the known BMC diﬀerences between
blacks versus nonblacks and boys versus girls. Tanner stage
was included in the models if it was statistically signiﬁcant.
A series of sequential regression analyses was performed to
evaluate diﬀerences in BMC between the BA and control
groups when accounting for the eﬀects of (1) gender, black
ethnicityandage,(2)sameasthepreviousmodel,plusheight
and Tanner stage (if statistically signiﬁcant), and (3) same as
the previous model plus an interaction term (biliary atresia
x age) to test for age-related declines in BMC status in the
BA group after accounting for other important covariates.
The eﬀect of BA in each multivariate model is presented in
the text as the adjusted ratio of the outcome measure (e.g.,
lumbar spine BMC or whole body BMC) divided by the
outcome measure in the controls, with 95 percent conﬁdence
intervals. The adjusted ratio and conﬁdence intervals were
calculated as the exponentiated estimates of the regression
variables for BA.
The diﬀerence between the BA and control group was
expressed as the adjusted ratio of the outcome measure in
the subjects with BA divided by the outcome measure in
the control subjects, with 95% conﬁdence intervals. The
adjusted ratio and conﬁdence intervals were calculated as the
exponentiated estimates of the regression parameters.
The regression models described above (Table 2,m o d e l
2) were used to generate standardized residuals for whole
body and lumber spine BMC for the subjects in the BA
group. The standardized residuals were used to represent
standard deviation scores, similar to Z-scores, for BMC
adjusted for sex, black ethnicity, age, height, spine BMC, and
Tanner stage.
Spearman tests were performed to examine the correla-
tion of serologic tests (total bilirubin, direct bilirubin, andGastroenterology Research and Practice 3
Table 1: Subject characteristics between the ages of 3 and 18.
Biliary atresia Controls P
n 16 11 178
Age (year) Range
7.3 ± 1.48 .0 ± 3.69 .6 ± 3.7. 1 7
4.0 to 18.6
Gender 9 M/7 F 6 M/5 F 76 M/109 F .38
Race (% African American) 81 0 3 9 . 0 4
Tanner distribution
(n at stages 1, 2, 3, 4, 5)
(15, 0, 1, 1, 0) (9, 0, 1, 1, 0) (114, 27, 15, 21, 8) .59
Height z-score −0.31 ± 0.21 −0.11 ± 0.62 0.37 ± 1.10 .14
BMI z-score 0.24 ± 0.28 0.18 ± 0.63 0.34 ± 1.10 .64
Weight z-score 0.05 ± 0.27 −0.21 ± 0.62
Serum alanine transferase (U/L)1 78.4 ± 12.05 6 .8 ± 34.6
Serum albumin (g/dL) 3.7 ± 0.23 .8 ± 0.64
Serum total bilirubin (mg/dL)2 2.4 ± 0.90 .9 ± 0.5
Serum direct bilirubin (mg/dL)3 0.24 ±1.00 .18 ± 0.13
Serum alkaline phosphatase 267 ± 136 234 ± 108
Serum 25–OH vitamin D (ng/mL)4 24.3 ± 5.12 6 ± 5.9
Bone age delay (Years)5 0.19 ± 0.38 0.24 ± 1.34
Mean ± SD
1Data available for 9 subjects
2Data available for 10 subjects
3Data available for 10 subjects
4Data available for 6 subjects
5Data available for 9 subjects
alanine transferase) and BMC standardized deviation score
of both the spine and whole body (Table 3).
3. Results
3.1. Subject Characteristics. A total of 16 BA patients were
enrolled in the study. Anthropometric measurements of
height and weight were compared to the U.S. Reference
Data set (CDC 2000). Although mild stunting was present
as indicated by the mean height-for-age z-score (HAZ) of
−0.31, the weight age z-score (WAZ) and body mass index
z-score (BMIZ) were essentially normal. Eight of 16 subjects
received vitamin D supplementation prescribed by their
primary liver physician. No signiﬁcant diﬀerence in mean
vitamin D level was found between those on supplements
and those not. All subjects had normal 25–OH vitamin
D levels, with a mean of 24.3ng/mL and none of the
subjects were frankly deﬁcient (<10ng/mL). Calcium intake
based on three diet records analyzed by Food Processor
ranged from 90% to 210% of for age-based comparisons. No
signiﬁcant bone age delay existed. Linear regression analyses
w e r ec o n d u c t e dt oc o m p a r et h eB M Di nB As u b j e c t st ot h e
Hologic age-matched normative data. The linear regression
line of BMD z-scores versus age showed that 42% of the
variance was explained by age (P = .0007), suggesting a
decline in BMD with age (Figure 1).
We explored the relationship of confounding variables
on our ﬁnding using a carefully phenotyped control cohort
that included ethnicity and tanner. A total of 11 patients
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Figure 1: BMD Z-Score versus age.
with BA were studied in this cohort. The 5 youngest patients
were excluded due to the age range of the control cohort.
Characteristics of the BA subjects are shown in Table 1.M i l d
stuntingwaspresent,asindicatedbythemeanheight-for-age
z-score (HAZ) of −0.11, while the body mass index z-score
(BMIZ) was in the normal range. Compared to controls, BA
subjects’ HAZ and BMIZ were not signiﬁcantly diﬀerent.
Both mean age and percentage African American subjects4 Gastroenterology Research and Practice
were less in the BA group but these diﬀerences were only
signiﬁcantforthepercentageAfricanAmericansubjects(P =
.04). For the BA group (n = 6), the mean 25–OH vitamin D
concentration was 26ng/mL, and none of the subjects were
frankly deﬁcient (<10ng/mL). Only one of eleven subjects
had a total bilirubin level greater than 1.00mg/dL and that
subject had a direct bilirubin of 0.00mg/dL. The mean direct
bilirubin level for the cohort of BA subjects was 0.18mg/dL.
Nosigniﬁcantboneagedelayexistedandnoneofthesubjects
had a prior fracture. In addition, none of the subjects were
receiving vitamin D supplementation.
3.2. DXA Results. The distribution of BMC for age in BA
subjectscomparedtocontrolsisillustratedinFigures2and3.
The distribution suggests that low BMC status may be more
likely to occur at older ages. It also illustrates the nonlinear
and heteroscedastic distribution of BMC relative to age in
growing children.
3.2.1. Lumbar Spine BMC. The sequential regression models
to evaluate BMC in BA compared to controls are shown
in Table 2. Model 1 evaluated spine BMC adjusted for age,
black ethnicity and gender. BMC was signiﬁcantly reduced
in subjects with BA. The adjusted ratio for spine BMC in
subjects with BA compared with controls was 0.87 (95%
C.I. 0.76, 0.98), R2 = 0.82, P ≤ .001). However, the
reduced BMC for age may be due to decreased height for
age in the BA group, and subsequently smaller bones for age.
Delayed puberty may also have an eﬀect on BMC status. In
model 2, height and Tanner stage were added to the model.
Adjustment for these covariates attenuated the deﬁcits in
BMC and the explained variance (overall R2) increased;
however, the deﬁcits remained signiﬁcant. The fullyadjusted
ratio of spine BMC in the BA subjects compared with
controls was 0.88 (95% C.I. 0.80, 0.97, R2 = 0.90, P<. 001).
That is, BMC was 12% lower, on average, in BA subjects
compared with controls. Model 3 shows that the interaction
term for BA x age was statistically signiﬁcant and negative,
indicatingthattheadverseeﬀectofBAonlumbarspineBMC
was greater at older ages. However, there was no appreciable
increase in the overall R2 for the model.
3.2.2. Whole Body BMC. The initial model for whole body
BMC shown in Table 2 evaluated whole body BMC in
subjects with BA compared with controls, adjusted for age,
gender and black ethnicity. The adjusted ratio for whole
body BMC in subjects with BA compared with controls
was 0.88 (95% C.I. 0.78, 1.00, R2 = 0.85, P<. 001).
The model was then adjusted for height; Tanner stage was
not statistically signiﬁcant and was therefore excluded from
this and subsequent models. Whole body BMC remained
signiﬁcantly decreased in the subjects with BA compared
with control subjects: ratio 0.91 (95% C.I. 0.83, 0.99, R2 =
0.93, P<. 001). That is, whole body BMC was 9% lower
on average, adjusted for height, age, gender, and race in the
BA subjects compared with controls. Model 3 shows that the
interaction term for BA x age was statistically signiﬁcant and
negative, indicating that the adverse eﬀect of BA on whole
body BMCwasgreateratolderages.However,therewasonly
a modest increase in the overall R2 for the model.
Analyses of direct bilirubin, total bilirubin and alanine
transferase were performed using Spearman tests to inves-
tigate correlations between these serologic tests and BMC
standard deviation score. A signiﬁcant negative correlation
was identiﬁed for direct bilirubin level and spine BMC
z-score and a trend toward a negative relationship was
identiﬁed for whole body BMC z-score. (Table 3).
4. Discussion
These analyses demonstrate the existence of a signiﬁcant
bonemineraldeﬁcitinacohortofnonjaundicedBApatients.
In part, bone mineral deﬁcits were due to smaller body size,
but signiﬁcant deﬁcits were observed even after adjusting
for height. In this BA population, the magnitude of spine
and whole body deﬁcits were signiﬁcantly greater in older
subjects, even when adjusted for confounding variables
including gender, pubertal status, race, and height. In other
words, bone deﬁcits relative to age in children with BA were
due, in part, to factors related to growth and maturation.
However, most importantly even taking these factors into
account, children with BA have bone deﬁcits of the spine and
whole body.
Our study is one of only a few to investigate bone mass
in nonjaundiced subjects with BA. It is unique because
of the important use of an appropriate comparison group
of healthy subjects and the examination of the eﬀects of
body size, race and maturation on bone mineral status, all
variables that have previously shown to lead to inaccuracies
of DXA interpretations [28]. Despite showing that non-
jaundiced participants with BA had depressed bone health,
our study has some limitations. Our sample size was small
(n = 16). Additionally, while our results show a statistically
signiﬁcant decline in BMC with age, our data are cross-
sectional and must be conﬁrmed with longitudinal data. The
results from this study serve as preliminary data that should
beusedastheimpetustoconductalarger,longitudinalstudy
of children with BA through age 18 to further investigate the
association of BMC with age.
Scant studies have examined rigorously the bone health
of nonjaundiced, long-term survivors of BA. Studies that
have addressed bone health in this population have often
been compromised by extremely small sample populations
[29, 30], the use of single beam photon absorptiometry
to measure BMD [29, 30], and focus on a younger BA
population [30, 31]. In contrast, our sample size was slightly
larger than in these previous studies, we used DXA to
measure BMC, and our age range allowed for a better
indication of the long-term eﬀects of BA on BMC. Further,
our study included a more robust control population that
permitted adjustment for age, gender, race, maturation, and
body size.
Itiswellknownthatbonehealthcanbeimpactedbymal-
absorption, vitamin K deﬁciency and vitamin D deﬁciency
[3,32,33].Andrewsetal.[32],studiedradiographsofasmall
group of post-Kasai subjects with BA to look for evidenceGastroenterology Research and Practice 5
Table 2: Multivariable regression models of lumbar spine and whole body BMC in biliary atresia versus control groups adjusting for age,
gender, race and height.
Coef. Std. Err. tP > |t| R2
Lumbar spine BMC
Model 1 Female gender 0.04 0.03 1.38 0.169 0.82
Black ethnicity 0.07 0.03 2.16 0.032
Age −1.36 0.39 −3.51 0.001
Age2 0.56 0.09 6.21 0.000
Biliary atresia −0.14 0.06 −2.21 0.028
Intercept 3.38 0.41 8.26 0.000
Model 2 Female gender 0.04 0.02 1.60 0.112 0.90
Black ethnicity 0.02 0.02 0.95 0.341
Height 2.37 0.23 10.39 0.000
Age −1.58 0.41 −3.84 0.000
Age
2 0.39 0.10 4.08 0.000
Tanner stage 2 −0.05 0.04 −1.38 0.169
Tanner stage 3 0.05 0.05 0.97 0.333
Tanner stage 4 0.14 0.06 2.14 0.034
Tanner stage 5 0.25 0.08 2.93 0.004
Biliary atresia −0.12 0.05 −2.58 0.011
Intercept −6.95 0.93 −7.45 0.000
Model 3 Female gender 0.03 0.02 1.52 0.080 0.90
Black ethnicity 0.02 0.02 0.94 0.068
Height 2.35 0.23 10.39 2.802
Age −1.34 0.43 −3.14 −0.498
Age
2 0.34 0.10 3.43 0.536
Tanner stage 2 −0.06 0.04 −1.47 0.019
Tanner stage 3 0.06 0.05 1.10 0.166
Tanner stage 4 0.15 0.06 2.31 0.272
Tanner stage 5 0.26 0.08 3.06 0.420
Biliary atresia 0.26 0.22 1.20 0.697
Biliary atresia∗Age −0.19 0.11 −1.81 0.017
Intercept −7.14 0.93 −7.66 −5.303
Whole body BMC
Model 1 Female gender 0.02 0.03 0.78 0.435 0.85
Black ethnicity 0.14 0.03 4.38 0.000
Age −0.50 0.40 −1.25 0.214
Age
2 0.39 0.09 4.24 0.000
Biliary atresia −0.12 0.07 −1.90 0.059
Intercept 5.93 0.42 14.01 0.000
Model 2 Female gender 0.02 0.02 0.73 0.467 0.93
Black ethnicity 0.09 0.02 4.19 0.000
Height 2.88 0.21 13.88 0.000
Age −1.65 0.29 −5.67 0.000
Age
2 0.42 0.06 6.59 0.000
Biliary atresia −0.10 0.05 −2.18 0.031
Intercept −5.81 0.90 −6.48 0.0006 Gastroenterology Research and Practice
Table 2: Continued.
Coef. Std. Err. tP > |t| R2
Model 3 Female gender 0.01 0.02 0.58 0.563 0.93
Black ethnicity 0.09 0.02 4.26 0.000
Height 2.88 0.21 14.04 0.000
Age −1.44 0.30 −4.71 0.000
Age
2 0.38 0.07 5.64 0.000
Biliary atresia 0.35 0.21 1.69 0.094
Biliary atresia∗Age −0.22 0.10 −2.21 0.028
Intercept −6.07 0.89 −6.79 0.000
∗All continuous variables (spine and whole body BMC, age, and height) were natural log transformed.
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Figure 2: Age versus lumber spine bone mineral content in BA subjects compared to controls.
of osteomalacia. They determined that 24% of subjects
with “successful” Kasai exhibited radiographic evidence of
osteomalacia. However, their results were hindered by the
lack of serum vitamin D concentrations and a deﬁnition
of “successful” Kasai. A more recent study by Bucuvalas
et al. [34], examined serum 25–OH vitamin D in nine
subjects with cholestatic liver disease. Based on the growing
recognition that vitamin D optimization occurs at 25–OH
vitamin D concentrations greater than 30ng/mL [35], 56%
of their subjects were suboptimal, similar to the prevalence
found in healthy children [36]. Our study found low 25–
OH vitamin D levels among subjects with BA with good
post-Kasai outcomes; however, data were only available for
half of the participants. While these data do not suﬃciently
support an assertion of vitamin D deﬁciency, it is possible
that vitamin D status may have been one determinant of
bone health in our cohort.
Of note is the study performed by Toki et al. [37],
which is most closely comparable to ours and substantiates
our results. They found two of eight nonjaundiced subjects
with BA to have depressed bone health with the presence
of normal serum vitamin D, although their deﬁnition of
normal serum vitamin D status was not given. While they
do not speciﬁcally address their reference population, we
used ours to account for the confounding variables often
present in pediatric bone studies [27, 38–41]. The combined
results from Toki et al. [37] and our study indicate that
compromised bone health may be detected in the absence
of severe vitamin D deﬁciency and therefore warrant future
investigations into bone health in nonjaundiced subjectsGastroenterology Research and Practice 7
Table 3: Spearman correlation of bone mineral content and serologic tests.
Spine Z Whole body Z
Rho nP Rho nP
Direct bilirubin −0.64 10 .04 −0.53 10 .11
Total bilirubin −0.09 10 .81 −0.36 10 .31
ALT −0.18 9 .65 −0.12 9 .76
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Figure 3: Age versus whole body bone mineral content in BA subjects compared to controls.
withBA.Anotherconsiderationwouldincludeexploringany
relationships that may exist concerning portal hypertension
and bone mineral status.
Optimizing peak bone mass is of utmost importance
during childhood and adolescence; it lays the foundation for
good bone mineral status through adulthood. Even though
past literature has focused on dietary calcium and both
dietary and serum vitamin D [10, 34, 40, 42], it is now
recognized that inﬂammation is important and may play a
role in bone health [6, 9, 12, 43, 44]. This newest area of
research focuses on a group of inﬂammatory cytokines such
as Interleukin-6 [6, 9, 11–13], Interleukin-1 [6, 9, 12, 13],
Interleukin-11 [9], and tumor necrosis factor alpha [6, 9,
12, 13], as potential modiﬁers of bone metabolism that
predominantly impair bone formation and promote bone
resorption. A recent study by Uchida et al. [22]p r o v i d e d
preliminary evidence that various interleukins may aﬀect
bone health. However, the study only looked at speciﬁc
interleukins (Interleukin-6, Interleukin-1 and hepatocyte
growth factor). Further studies are needed to evaluate the
role of inﬂammatory factors in bone mineral accretion in
a larger sample of children with BA. Most importantly this
serves as a bench mark for interventional studies designed to
optimize bone health in children.
5. Conclusion
Signiﬁcant bone mineral deﬁcits were identiﬁed in a cohort
of nonjaundiced BA patients in this study. The focus on a
nonjaundiced population, the sample size and the correc-
tion for confounding variables makes this a unique study.
Pediatric bone health is a priority often overlooked, but is a
signiﬁcant concern because of its long-term implications. It
is important to focus on bone health during childhood and
adolescencewhenbonemineralcontentisincreasingrapidly.
Achieving optimal peak bone mass is a major determinant
of lifelong bone health and prevention of osteoporosis later
in life [10]. These data suggest that bone mineral status in
children with BA may decline with age during childhood. A8 Gastroenterology Research and Practice
larger prospective study is needed to examine bone mineral
accretion in this population to identify its determinants, so
that eﬀective interventions and strategies can be developed
to prevent or treat poor bone health.
Abbreviations
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BMC: Bone mineral content
BMD: Bone mineral density
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